PENFLURIDOL (R 16 341) AS A MAINTENANCE THERAPY IN CHRONIC PSYCHOTIC PATIENTS: A DOUBLE‐BLIND CLINICAL EVALUATION

@article{Roelofs1974PENFLURIDOL1,
  title={PENFLURIDOL (R 16 341) AS A MAINTENANCE THERAPY IN CHRONIC PSYCHOTIC PATIENTS: A DOUBLE‐BLIND CLINICAL EVALUATION},
  author={G. A. Roelofs},
  journal={Acta Psychiatrica Scandinavica},
  year={1974},
  volume={50}
}
  • G. Roelofs
  • Published 1 April 1974
  • Medicine, Psychology
  • Acta Psychiatrica Scandinavica
A double‐blind, 6‐month trial of penfluridol and placebo was conducted in 15 chronic psychotic patients in the age range of 25–64 years. The patients, who had been well controlled with penfluridol for several months, were divided into two comparable groups with seven patients receiving penfluridol and eight receiving placebo. Dexetimide and other non‐psychotropic drugs already taken before the trial were continued. Each patient was assessed before and after 1, 2, 4 and 6 months of treatment… 
View on Wiley
ncbi.nlm.nih.gov
11 Citations

11 Citations

A DOUBLE‐BLIND CLINICAL EVALUATION OF PENFLURIDOL (R 16 341) AS A MAINTENANCE THERAPY IN SCHIZOPHRENIA

Twenty‐one female schizophrenics (age range 34–74 years) were included in a clinical study assessing the effectiveness of penfluridol as a basic maintenance therapy. At the start of the study, the…

PERORAL AND PARENTERAL ADMINISTRATION OF LONG‐ACTING NEUROLEPTICS: A DOUBLE‐BLIND STUDY OF PENFLURIDOL COMPARED TO FLUPENTHIXOL DECANOATE IN THE TREATMENT OF SCHIZOPHRENIA

Fifty‐six out of 60 schizophrenic patients completed a double‐blind study of two long‐acting neuroleptics, penfluridol (peroral) and flupenthixol decanoate (parenteral). Half of the patients were on…

Penfluridol steady‐state kinetics in psychiatric patients

Twenty‐two hospitalized schizophrenic patients, participating in a large‐scale phase II double‐blind dose‐effect study of penfluridol, a new diphenylbutylpiperidine neuroleptic, were maintained on a regular dosage regimen for 13 wk, showing that the peak concentration develops within 12 hr after the last dose.

Penfluridol for schizophrenia.

BACKGROUND Penfluridol, available since 1970, is an unusual long acting oral antipsychotic agent for the treatment of schizophrenia. It may be considered a depot medication as it is administered once…

The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics

Patients with schizophrenia have a lower risk of relapse and remain relapse free for a longer period of time compared with placebo and intermittent treatment strategies, and continuous treatment remains the ‘gold standard’ for good clinical practice.

Depot Antipsychotic Drugs

SummaryThe pharmacokinetics of depot antipsychotic medications are such that an intramuscular injection given at intervals of from 1 to 4 weeks will produce adequate plasma concentrations that are…

Maintenance treatment with antipsychotic drugs for schizophrenia.

The efficacy of antipsychotic drugs for maintenance treatment in schizophrenia was clear and hospitalisation was reduced and underpowered data revealed no evidence of a difference between groups for the outcome 'Death due to suicide'.

Weekly Supervised Administration of Oral Antipsychotics: An Alternative to Long-Acting Injections?

To be suitable for once-weekly administration as an oral formulation, an antipsychotic needs to have a sufficiently long duration of action and to be well tolerated in high doses.

Maintenance treatment with antipsychotic drugs for schizophrenia.

The efficacy of antipsychotic drugs for maintenance treatment in schizophrenia was clear and the results of the primary outcome were robust in a number of subgroup, meta-regression and analyses.

A historical review of placebo-controlled, relapse prevention trials in schizophrenia: The loss of clinical equipoise

References

SHOWING 1-10 OF 14 REFERENCES

Penfluridol: A Long‐Acting Oral Neuroleptic.

The data obtained from this study have tended to confirm the impression of previous investigators that penfluridol, administered in a dosage of 40 to 80 mg on a once-a-week basis in a single dose, compares favorably with the antipsychotic activity of those neuroleptics requiring administration on a daily basis.

Controlled Trial of Penfluridol in Acute Psychosis

Blood and neoplastic diseases. Solid tumours in children.

Dramatic improvements have resulted from the use of more effective combination chemotherapy regimens, augmented by radiotherapy in the prophylactic treatment of the central nervous system, so that leukaemia-free five year survival rates of over 50% have now been reported.

FLUSPIRILENE, AN INJECTABLE, AND PENFLURIDOL, AN ORAL LONG‐ACTING, NEUROLEPTIG

Interaction between neuroleptic therapy and sociotherapeutic approach an investigation with penfluorid and haloperidol.

Fluspirilene, an injectable, and penfluridol, an oral long-acting, neuroleptic. A comparative double-blind trial in residual schizophrenia.

Maintenance therapy of chronic psychostic patients with a weekly oral dose of R 16 341. A controlled double-blind study.

Lommel (1970a): Interaction between neuroleptic therapy and sociotherapeutic approach. An investigation with pen fluridol and haloperidol

  • Seventh Congress of the Collegium Internationale Neuro-Psychopharmacologicum, Prague, Czechoslovakia. (Available on request to the Janssen Research Products Information Service)
  • 1970

Penfluridol (R 16 341), a long-acting oral neuroleptic, as maintenance therapy for schizophrenic and mentally retarded patients

  • Psychiat. Neurol. Neurochir
  • 1973

Clinical evaluation of the weekly oral administration of penfluridol (R 16 341) in chronic psychotic patients

  • Seventh Congress of the Collegium International Neuro-Psychopharmacologicum, Prague, Czechoslovakia. (Available on request to the Janssen Research Products Information Service)
  • 1970